Gene amplification and overexpression of HER2 has been reported in for instance gastric- and endometrial cancers and urothelial bladder carcinoma [7], yet its clinical significance is perhaps best documented in breast cancer where these events have therapeutic implications [8]. Here, ERBB2 is linked to breast cancer.